Navigation Links
The University of Maryland Baltimore (UMB) and Paragon Bioservices, Inc. Announce the Formation of a Public-Private Stem Cell Technology Consortium
Date:4/28/2011

BALTIMORE, April 28, 2011 /PRNewswire/ -- UMB's Center for Stem Cell Biology and Regenerative Medicine and Paragon Bioservices, Inc., a contract research and GMP manufacturing organization with its headquarters at the University of Maryland BioPark, announced today the formation of a public-private partnership for developing and manufacturing stem cell therapies.

Dr. Curt I. Civin, Director of the University of Maryland's Center for Stem Cell Biology and Regenerative Medicine, a pioneer in cancer research and an internationally renowned physician-scientist who has made significant contributions in the field of blood-forming stem cell transplantation, stated "The main objective of the consortium is to accelerate the development of novel strategies for regenerative medicine, including new treatments and preventatives derived from stem cell research."

The Center will collaborate with Paragon Bioservices to establish a core facility that will offer stem cell services on a fee-for-service basis.  The services offered include cell banking and production of a variety of stem cell types.  Stem cells will be available for research purposes and, eventually, for clinical use. http://www.paragonbioservices.com/Research-Services/Stem-Cell-Services.aspx

The Consortium is being funded in part by a "Translational Research Award " from the Maryland Biotechnology Center.  According to Dr. Judy Britz, The MBC's Executive Director, "The Maryland Biotechnology Center evaluated 60 proposals and The Consortium effectively competed for its award since it is dedicated to crossing the translational medicine divide, creates a model for sustainability and increases the likelihood of commercialization of new technologies."

Dr. Marco Chacon, Paragon's President & CEO, commented, "It is an honor to work with Dr. Civin as well as a privilege to play a role in the development of interesting technologies that could have a positive impact on public health and the economic development of our community."

The partnership also includes Life Technologies, Inc., a global biotechnology company that is a provider of scientific products and reagents.  LTI already provides innovative solutions for scientists engaging in stem cell research.  So—as part of their corporate commitment to global social responsibility—they will be providing training opportunities for research scientists.

As a partnership for better public health, the Consortium is openly seeking wider participation from other research institutions, State and Federal agencies, and private companies.Contact:

Dr Aaron HeifetzBusiness DevelopmentStem Cell Technologies & Regenerative MedicineAbout Paragon Bioservices, Inc.Paragon Bioservices is a contract research and manufacturing organization (CMO) that provides a comprehensive portfolio of services—from research services and process development to cGMP manufacturing of monoclonal antibodies, therapeutic proteins, vaccines (VLPs), and stem cells.  The corporate focus is to bridge the translational divide and enable protein and cell-based therapeutics to move into clinical trials.  www.paragonbioservices.com

Media Contact for Paragon Bioservices:
Tiberend Strategic Advisors, Inc.
212-827-0020
Tamara Bright
tbright@tiberend.com
or
Claire Sojda
csojda@tiberend.com


'/>"/>
SOURCE Paragon Bioservices, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011
2. Tomophase Announces First Sale of Its OCT Imaging System (OCTIS™) for Research Use to the University of Texas
3. Nanocrystal doping developed by Hebrew University researchers enhances semiconductor nanocrystals
4. Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome
5. China PharmaHub In-Licenses Universal Donor Red Blood Cells Technology Exclusively From University of California, San Diego
6. Mtech Announces Semifinalists for University of Maryland $75K Business Plan Competition
7. University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks
8. Queens University professor uses nanotechnology to prolong machine and engine life
9. Binghamton University nanoscientist chosen for the Air Forces Young Investigator Research Program
10. Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh
11. Georgia Health Sciences University Clinical Study Shows RyMed InVision-Plus® IV Connector Significantly Decreased Central Venous Catheter Occlusions in Oncology Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Diego, CA (PRWEB) , ... December 01, 2016 , ... ... data from its Phase I/II clinical trials for AC0010 at the World Conference on ... forward to providing an update on the phase I/II clinical trials for AC0010 in ...
(Date:12/2/2016)... ... , ... The Conference Forum has announced that the 3rd annual Immuno-Oncology ... February 1-3, 2017 at the Roosevelt Hotel in New York City. Led by advisors ... 360-degree approach, which addresses the most up-to-date information regarding business aspects, clinical advancements and ...
(Date:12/2/2016)... ... December 02, 2016 , ... Robots will storm the Prudential Center in Boston, ... The event, which is held on the United Nations International Day of Persons with ... into the workplace. Suitable Technologies is partnering with NTI to showcase how technology can ...
(Date:11/30/2016)... ... November 30, 2016 , ... BEI Kimco, a ... with a flexure design that ensures high alignment accuracy by preventing unwanted shaft ... ideally suited where extreme precision is required, such as in medical equipment, laboratory ...
Breaking Biology Technology:
(Date:11/15/2016)... Nov. 15, 2016  Synthetic Biologics, Inc. (NYSE ... focused on the gut microbiome, today announced the ... shares of its common stock and warrants to ... a price to the public of $1.00 per ... Biologics from the offering, excluding the proceeds, if ...
(Date:6/27/2016)... -- Research and Markets has announced the addition of ... their offering. The report forecasts ... grow at a CAGR of 12.28% during the period 2016-2020. ... market analysis with inputs from industry experts. The report covers the ... report also includes a discussion of the key vendors operating in ...
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
Breaking Biology News(10 mins):